HBIO

Business Context and Reporting Period

Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: The Company designs, manufactures, and distributes apparatus, instruments, devices, and consumables for research scientists in pharmaceutical, biotechnology, university, and government laboratories. The reporting period reflects strong organic growth driven by new product launches (syringe pumps and spectrophotometers) and the integration of the Denville Scientific acquisition completed in September 2009.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 43.5% ($7.9M) for the quarter and 40.6% ($15.1M) for the six months compared to the prior year periods. This growth was driven primarily by the Denville Scientific acquisition, which contributed $6.5M (quarter) and $12.2M (six months) in revenue.
• Organic Growth: Excluding Denville and currency effects, organic revenue growth was 11% for the quarter and 7.4% for the six months, attributed to new product introductions and sales force expansion.
• Profitability: Net income surged to $1.9M for the quarter (from $0.3M) and $4.1M for the six months (from $2.1M). Operating income increased significantly due to revenue expansion and a $0.4M gain from the adjustment of acquisition contingencies related to Denville.
• Margins: Gross margin percentage decreased to 46.5% (quarter) and 47.6% (six months) from 49.5% and 49.4% respectively, primarily due to the lower-margin profile of the Denville business (which distributes rather than manufactures products).
• Debt Reduction: Long-term debt decreased from $13.3M at year-end 2009 to $11.2M at June 30, 2010, following net repayments of $2.2M during the first half of the year.

Guidance, Outlook, and Risks

• Outlook: Management expects available cash, operating cash flow, and debt capacity to be sufficient to finance operations for 12 months and beyond. The Company anticipates launching a clinical version of its syringe pump in 2011.
• Strategic Initiatives: Continued focus on "tuck-under" acquisitions, organic growth, and operational improvements. Significant investment is being made in regenerative medicine tools (bioreactors and injectors).
• Capital Allocation: The Company has $3.2M remaining under its stock repurchase program, expected to be spent in the third quarter of 2010. Capital expenditures for 2010 are estimated at $1.2M.
• Risks:
  • Foreign Exchange: Significant exposure to the British pound and Euro; a stronger U.S. dollar negatively impacted revenue by $0.7M in the quarter.
  • Acquisition Integration: Risks associated with successfully integrating acquired businesses and realizing projected synergies.
  • Regulatory: Potential delays in FDA approval for new clinical products due to evolving safety requirements for infusion pumps.
  • Valuation Allowance: The Company maintains a valuation allowance against U.S. deferred tax assets; a reversal could materially impact future effective tax rates.

Investor Verification Checklist

• Denville Contribution: Verify the sustainability of revenue and margin contributions from the Denville Scientific acquisition, which significantly altered the Company's product mix and margin profile.
• Organic Growth Rate: Confirm the 11% organic growth rate cited by management, excluding the impact of acquisitions and foreign currency fluctuations.
• Debt Covenants: Review compliance with the $20M revolving credit facility covenants (income, debt coverage, working capital), noting the current $8.8M available borrowing capacity.
• Regenerative Medicine Pipeline: Assess the commercial viability and regulatory timeline for the new bioreactor and clinical syringe pump products.
• Stock Repurchase Program: Monitor the execution of the remaining $3.2M stock repurchase authorization and its impact on share count and EPS.